Company Filing History:
Years Active: 2025
Title: Jolien Van Santbergen: Innovator in FcRn/HSA Binding Molecules
Introduction
Jolien Van Santbergen is a prominent inventor based in Ghent, Belgium. She has made significant contributions to the field of biomedicine, particularly in the development of binding molecules that target the human neonatal Fc receptor (FcRn). Her innovative work has the potential to impact treatments for antibody-mediated disorders.
Latest Patents
Jolien holds a patent for "FcRn/HSA binding molecules and methods of use." This patent includes binding molecules that comprise a human neonatal Fc receptor binding molecule and at least one antigen-binding domain linked to the FcRn binding molecule. Additionally, it covers polynucleotides, vectors, host cells, and methods of production. The patent also outlines methods for treating antibody-mediated disorders using the FcRn/antigen-binding molecule.
Career Highlights
Jolien is currently associated with Argenx BV, a company known for its focus on innovative therapies for severe autoimmune diseases. Her work at Argenx has positioned her as a key player in the development of novel therapeutic solutions.
Collaborations
Jolien collaborates with notable colleagues, including Vladimir Bobkov and Karen Silence. Their combined expertise contributes to the advancement of research and development in their field.
Conclusion
Jolien Van Santbergen's contributions to the field of binding molecules and her innovative patent highlight her role as a leading inventor in biomedicine. Her work continues to pave the way for new treatment options for patients with antibody-mediated disorders.